ArticleThe journal of allergy and clinical immunology. Global2024
Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient.
Article in The journal of allergy and clinical immunology. Global, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The Concurrence of Atopic Dermatitis and Alopecia Areata: How Common Is It? Why Does It Happen? How Is This Managed Optimally in Clinical Practice?The Journal of clinical and aesthetic dermatology · 2026Review
- Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series.Reports (MDPI) · 2026Article
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature.Frontiers in medicine · 2026Article
- Upadacitinib for Alopecia: Current Evidence and Clinical Insights.Skin appendage disorders · 2025Review
- Three versions of an atopic dermatitis case report written by humans, artificial intelligence, or both: Identification of authorship and preferences.The journal of allergy and clinical immunology. Global · 2025Article
- Dramatic clearance of extensive psoriasis in a pediatric patient treated with upadacitinib: A case report.SAGE open medical case reports · 2025Article
- Drug-Induced Alopecia Areata From Upadacitinib.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 29-year-old male patient had severe atopic dermatitis (AD) and alopecia universalis (AU) that could not be controlled by using classic therapy. He started taking upadacitinib and achieved an excellent response for both his AD and AU. Thus, upadacitinib represents a promising therapeutic approach for patients with severe AD and alopecia areata.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.